
How pharma is tackling new direct-to-patient programmes
At Reuters Pharma USA, executives from AstraZeneca, Gilead, Kyowa Kirin, and EVERSANA discussed the what, why, and how of direct-to-patient models.
Newsletters and Deep Dive digital magazine
At Reuters Pharma USA, executives from AstraZeneca, Gilead, Kyowa Kirin, and EVERSANA discussed the what, why, and how of direct-to-patient models.
Three studies of Sarepta's Elevidys Duchenne gene therapy have been placed on hold as the death of a 16-year-old boy is investigated.
Pharmaceuticals are exempt from the tariffs revealed by President Donald Trump, for now, but the industry is bracing for what may come next.
Observational research is core to drug development, helping researchers understand the natural history of diseases and the real-world impact of treatments on patients.
Editor's Picks
Newsletters and Deep Dive
digital magazine